No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 24K | 44K | 47K | 0 | 0 | 0 | 437K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -24K | -44K | -47K | 0 | 0 | 0 | -437K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -0.83% | -0.07% | 1% | - | - | - | 1% |
| Operating Expenses | 4.12M | 8.9M | 29.33M | 69.57M | 126.87M | 92.83M | 86.02M | 78.78M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 666K | 1.95M | 7.58M | 21.36M | 30.04M | 28.39M | 27.11M | 27.47M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 3.45M | 6.95M | 21.75M | 48.21M | 96.83M | 64.44M | 58.91M | 51.31M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -6K | -16K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.12M | -8.9M | -8.9M | -69.57M | -126.87M | -92.83M | -86.46M | -78.78M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -1.16% | 0% | -6.81% | -0.82% | 0.27% | 0.07% | 0.09% |
| EBITDA | -4.09M | -8.86M | -8.86M | -68.97M | -126.67M | -92.32M | -86.02M | -78.44M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -1.16% | 0% | -6.79% | -0.84% | 0.27% | 0.07% | 0.09% |
| D&A (Non-Cash Add-back) | 24K | 44K | 47K | 600K | 205K | 508K | 437K | 343K |
| EBIT | -4.12M | -8.93M | -29.33M | -67.25M | -126.87M | -92.83M | -86.46M | -78.78M |
| Net Interest Income | 0 | 0 | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M |
| Interest Income | 0 | 4K | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M |
| Interest Expense | 65K | 0 | 0 | 1K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -483K | -27K | -5.93M | 2.32M | 1.28M | 1.66M | 4.02M | 9.11M |
| Pretax Income | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | -27K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -0.94% | -2.95% | -0.91% | -0.87% | 0.27% | 0.1% | 0.15% |
| Net Income (Continuing) | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.64 | -0.64 | -1.15 | -2.04 | -3.47 | -2.52 | -1.88 | -1.27 |
| EPS Growth % | - | 0% | -0.8% | -0.77% | -0.7% | 0.27% | 0.25% | 0.32% |
| EPS (Basic) | -0.64 | -0.64 | -1.15 | -2.04 | -3.47 | -2.52 | -1.88 | -1.27 |
| Diluted Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M |
| Basic Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.91M | 51.68M | 155.71M | 319.55M | 215.7M | 127.71M | 134.03M | 101.18M |
| Cash & Short-Term Investments | 7.88M | 51.66M | 154.67M | 315.07M | 209.79M | 122.81M | 131.4M | 98.58M |
| Cash Only | 7.88M | 51.66M | 154.67M | 34.6M | 65.8M | 34.31M | 56.22M | 36.44M |
| Short-Term Investments | 0 | 0 | 0 | 280.46M | 143.99M | 88.49M | 75.18M | 62.14M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.9M | 2.63M | 2.6M |
| Total Non-Current Assets | 107K | 142K | 2.58M | 10.12M | 31.98M | 28.55M | 24.53M | 21.46M |
| Property, Plant & Equipment | 102K | 134K | 164K | 8.79M | 30.74M | 27.38M | 23.71M | 20.4M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5K | 8K | 2.42M | 1.33M | 1.24M | 1.17M | 823K | 1.07M |
| Total Assets | 8.02M | 51.83M | 158.29M | 329.67M | 247.68M | 156.25M | 158.57M | 122.64M |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | - | 5.46% | 2.05% | 1.08% | -0.25% | -0.37% | 0.01% | -0.23% |
| Total Current Liabilities | 2.23M | 2.58M | 4.86M | 14.22M | 23.64M | 15.26M | 19.65M | 20.57M |
| Accounts Payable | 152K | 416K | 1.96M | 2.54M | 4.11M | 1.88M | 2.32M | 4.01M |
| Days Payables Outstanding | 2.31K | 3.45K | 15.25K | - | - | - | 1.94K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x |
| Quick Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 12.47M | 64.79M | 200.59M | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M |
| Long-Term Debt | 0 | 60.77M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.47M | 4.02M | 200.59M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.7M | 67.37M | 205.45M | 21.91M | 51.78M | 40.56M | 41.83M | 39.35M |
| Total Debt | 12.46M | 60.77M | 0 | 8.74M | 28.46M | 28.14M | 25.3M | 22.19M |
| Net Debt | 4.58M | 9.11M | -154.67M | -25.86M | -37.34M | -6.17M | -30.92M | -14.25M |
| Debt / Equity | - | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -63.37x | - | - | -69570.00x | - | - | - | - |
| Total Equity | -6.67M | -15.54M | -47.16M | 307.76M | 195.9M | 115.69M | 116.74M | 83.28M |
| Equity Growth % | - | -1.33% | -2.03% | 7.53% | -0.36% | -0.41% | 0.01% | -0.29% |
| Book Value per Share | -0.93 | -1.11 | -1.31 | 9.35 | 5.41 | 3.19 | 2.66 | 1.51 |
| Total Shareholders' Equity | -6.67M | -15.54M | -47.16M | 307.76M | 195.9M | 115.69M | 116.74M | 83.28M |
| Common Stock | 1K | 1K | 1K | 5K | 5K | 5K | 7K | 7K |
| Retained Earnings | -6.78M | -15.71M | -50.97M | -118.22M | -243.82M | -334.99M | -417.43M | -487.11M |
| Treasury Stock | 56K | 100K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -56K | -100K | 0 | 614K | -414K | -1.82M | -27K | 24K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.35M | -8.45M | -24.67M | -52.15M | -100.15M | -85.08M | -66.72M | -62.3M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -2.6% | -1.92% | -1.11% | -0.92% | 0.15% | 0.22% | 0.07% |
| Net Income | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M |
| Depreciation & Amortization | 24K | 44K | 47K | 52K | 205K | 508K | 437K | 343K |
| Stock-Based Compensation | 5K | 64K | 3.64M | 7.76M | 14.04M | 12.2M | 9.6M | 10.63M |
| Deferred Taxes | 412K | 0 | 0 | 1.73M | 2.18M | 0 | 0 | 0 |
| Other Non-Cash Items | 66K | 15K | 6.43M | 524K | 2.01M | 3.28M | 2M | -905K |
| Working Capital Changes | 1.74M | 354K | 463K | 5.04M | 7.02M | -9.9M | 3.69M | -2.69M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -59K | 264K | 1.45M | 1.07M | 1.57M | -2.23M | 597K | 1.68M |
| Cash from Investing | -77K | -76K | -21K | -281.69M | 130.61M | 53.37M | 16.35M | 16.97M |
| Capital Expenditures | -77K | -76K | -21K | -142K | -2.71M | -192K | -33K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -118K | -2.7M | 0 | 95K | 0 |
| Cash from Financing | 9.97M | 52.31M | 127.76M | 214.94M | 729K | 177K | 71.93M | 25.55M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 10.02M | 0 | -1.74M | 1.1M | 0 | 0 | 82K | 1.05M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -2.43M | -8.53M | -24.7M | -52.29M | -102.86M | -85.27M | -66.75M | -62.3M |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -2.51% | -1.9% | -1.12% | -0.97% | 0.17% | 0.22% | 0.07% |
| FCF per Share | -0.34 | -0.61 | -0.69 | -1.59 | -2.84 | -2.35 | -1.52 | -1.13 |
| FCF Conversion (FCF/Net Income) | 0.51x | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -51.61% | -49.87% | -58.52% | -70.94% | -69.67% |
| Return on Invested Capital (ROIC) | - | - | - | -130.33% | -43.21% | -51.94% | -66.39% | -76.31% |
| Debt / Equity | - | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x |
| Interest Coverage | -63.37x | - | - | -69570.00x | - | - | - | - |
| FCF Conversion | 0.51x | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x |
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2024.
Black Diamond Therapeutics, Inc. (BDTX) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Black Diamond Therapeutics, Inc. (BDTX) is profitable, generating $21.5M in net income for fiscal year 2024 (30.7% net margin).
Black Diamond Therapeutics, Inc. (BDTX) has a return on equity (ROE) of -69.7%. Negative ROE indicates the company is unprofitable.
Black Diamond Therapeutics, Inc. (BDTX) generated $21.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.